Vivus Inc., seeking to reverse the Food and Drug Administration’s October rejection of its obesity-fighting drug Qnexa, said a long-term study shows that patients who took the drug used blood pressure pills 18.9 percent less.
After two years, patients in the study also saw a 26 percent drop in their levels of triglycerides, high levels of which are associated with obesity and heart disease, the Mountain View-based company (NASDAQ: VVUS) said.
The study is important for Vivus because the company must show that weight loss is tied to improvement of other obesity-related health markers.
No comments:
Post a Comment